Biological
Vi polysaccharide vaccine, typhoid clinical trials
Also written Typhim Vi and Typhoid Vi Polysaccharide Vaccine.
- studies test it
- 10
- open now
- 1
- in phase 3
- 2
- first study started
- 2011
Keep track of what changes. Save the Vi polysaccharide vaccine, typhoid studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Other names
Studies by the year they started
10 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2022 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 4
- Phase 1
- 3
- Phase 3
- 2
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 7
University of California, San Francisco (3) · Stanford University (1) · Universitaire Ziekenhuizen KU Leuven (1) · University of Virginia (1) · Texas A&M University (1) · Sanofi Pasteur, a Sanofi Company (1) · Janssen Pharmaceutica N.V., Belgium (1) · Novartis (1)
Often tested with
Tested in the same studies.
23-valent pneumococcal capsular polysaccharide vaccine (2) · Pneumococcal Vaccines (2) · Influenza Vaccines (1) · Hepatitis A Vaccines (1) · Ty21a Typhoid Vaccine (1) · Yellow Fever Vaccine (1) · Japanese Encephalitis Vaccines (1) · Rabies Vaccines (1)
Studies
Open first, then newest update. How each study uses Vi polysaccharide vaccine, typhoid is read from its arms, and is right about nine times in ten.
Testing it · 10
- Inflammatory Challenge and FearRecruitingPhase 1University of California, San FranciscoNCT06630884Written as Typhoid VI Polysaccharide Vaccine Injectable Solution
- Effects of Aging on Primary and Secondary Vaccine ResponsesCompletedPhase 1Stanford UniversityNCT03312699Written as Typhim Vi
- Polysaccharide Antibody Response StudyCompletedPhase 4Universitaire Ziekenhuizen KU LeuvenNCT02429531Written as Typhim Vi (Sanofi Pasteur MSD)
- Undetectable IgE as a Sentinel Biomarker for Humoral ImmunodeficiencyCompletedPhase 1University of VirginiaNCT03968211Written as Salmonella typhi polysaccharide vaccine
- Persistent Readiness Through Early Prediction Immunization StudyCompletedEarly Phase 1Texas A&M UniversityNCT05346302Written as Typhim VI
- Inflammation and Threat Sensitivity in PTSDCompletedEarly Phase 1University of California, San FranciscoNCT03048929Written as Typhoid Vi Polysaccharide Vaccine
- Cognitive, Emotional, and Neural Responses to Acute InflammationCompletedEarly Phase 1University of California, San FranciscoNCT03294564Written as Typhoid Vi Polysaccharide Vaccine
- Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese SubjectsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT01608815Written as Typhoid Vi polysaccharide
- Exploratory Study on the Mood and Cytokine Levels in Female Healthy Participants and Major Depressive Disorder PatientsCompletedEarly Phase 1Janssen Pharmaceutica N.V., BelgiumNCT01533285Written as Salmonella typhi vaccine (Typhim Vi)
- A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in AdultsCompletedPhase 3NovartisNCT01466387Written as Typhoid Vi Polysaccharide Vaccine
Given in every arm · 2 — Vi polysaccharide vaccine, typhoid is usual care beside what is tested
- Iron Fortified Food to Improve Japanese Encephalitis and Typhoid Fever Vaccine ImmunogenicityRecruitingNot applicableUniversity of OxfordNCT06027801Written as Typhoid Vi polysaccharide (Vi-PS) vaccine
- Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy VolunteersCompletedPhase 1Karolinska InstitutetNCT02286544Written as Salmonella typhi vaccine (Typhim Vi®)
As the comparator · 8 — what is tested is compared with Vi polysaccharide vaccine, typhoid
- Smallpox Vaccine for Mpox Post-Exposure Prophylaxis: A Cluster RCTActive, not recruitingPhase 4McMaster UniversityNCT05745987Written as Typhoid VI Polysaccharide Vaccine Injectable Solution
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and InfantsCompletedPhase 1/2GlaxoSmithKlineNCT05073003Written as Typhim-Vi
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid FeverCompletedPhase 1/2GlaxoSmithKlineNCT05480800Written as Sanofi Pasteur's Typhoid Vi polysaccharide vaccine
- Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy AdultsCompletedPhase 1GlaxoSmithKlineNCT05613205Written as Sanofi Pasteur's Typhoid Vi polysaccharide vaccine
- Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in MaliCompletedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT03917654Written as TYPHIM Vi (Salmonella typhi vaccine)
- Vaccines Against Salmonella TyphiCompletedPhase 2University of OxfordNCT02324751Written as Vi-PS Vaccine
- Safety and Immunogenicity of a Vi-DT Typhoid Conjugate VaccineCompletedPhase 1International Vaccine InstituteNCT02645032Written as Typhim Vi®
- Safety and Tolerability of Typhoid Conjugate Vaccine (EuTCV) in Healthy AdultsCompletedPhase 1EuBiologics Co.,LtdNCT03956524Written as Typhim Vi®
Codes
What other systems call Vi polysaccharide vaccine, typhoid · ClinicalTrials.gg INT003396
- RxNorm 807219One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 807219 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.